SkinMedica doubles R&D footprint to accelerate longevity innovation

Allergan Aesthetics has deepened its subsidiary SkinMedica’s footprint in regenerative science through investments that support innovation, research, clinical insight, and patient experience.

Focusing on regenerative science, the company’s advancements include expanding its R&D facility, adding a Regenerative Science Advisory Board, and the debut of flagship retail experiences to cater to consumer needs.

Innovation through R&D

Allergan Aesthetics, the aesthetic treatments and technologies company behind SkinMedica, is investing in its R&D lab in Irvine, California, US. The lab supports a range of pre-clinical research and imaging technologies that aim to provide insight into skin biology.

According to Allergan, SkinMedica is leveraging AI and machine learning to identify new biological targets, accelerate ingredient discovery, and boost understanding of skin longevity on the cellular level. These enhancements will work to address unmet skin concerns.

“By integrating advanced research capabilities with AI-enabled discovery and clinical expertise, we are accelerating our ability to transform breakthrough science into meaningful innovations that deliver for patients and providers,” says Prithwiraj Maitra, VP of global skin care R&D at Allergan Aesthetics.

With the expansion, the lab has more than doubled its previous footprint. It now brings formulation scientists, biological researchers, and clinical experts together to optimize, bolster, and modernize the development process of regenerative skin care solutions.

Advisory boards and patient insights

The expanded SkinMedica lab supports a range of pre-clinical research and imaging technologies.SkinMedica has also launched a Regenerative Science Advisory Board, bringing together physicians, clinicians, and skin health experts from the US. It aims to encourage scientific discourse, share clinical practices, and help combine research with everyday patient care. This is achieved through in-person collaboration, virtual consultations, and curated content across SkinMedica-owned platforms.

“Scientific innovation is most impactful when it is informed by the clinicians and experts who bring it to life every day,” says Glen Curran, SVP at Allergan Aesthetics.

“[The Regenerative Science Advisory Board’s] expertise and real-world perspective will help advance scientific education, strengthen collaboration across the aesthetic community, inform future conversations around skin longevity and innovation, while ensuring we continue to translate breakthrough science into meaningful solutions for providers and patients.”

In addition to its advisory board and R&D expansions, SkinMedica has launched its first in-practice flagship retail services at various aesthetics clinics in the US, where patients can purchase SkinMedica products.

The experiences aim to extend regenerative skin care beyond the practice by informing patients about SkinMedica products and exploring the personalized regimens recommended by their provider.